Biopharma Rethinks Strategy Amid U.S. MFN Pricing Shift
Global Pharma Grapples with U.S. MFN Pricing Sometimes, regulatory changes hit the industry like a freight train, and other times they creep in like the tide reshaping everything without much fanfare. The U.S. Most-Favored-Nation (MFN) pricing rule, spotlighted in a recent World ACCESS Consortium (WAC) white paper, might be the latter. It’s bending biopharmaceuticals'...
Continue Reading